Journal Information
Vol. 114. Issue 6.
Pages 536-540 (June 2023)
Share
Share
Download PDF
More article options
Visits
4620
Vol. 114. Issue 6.
Pages 536-540 (June 2023)
Brief Communication
Full text access
Wide Excision in Hidradenitis Suppurativa. Does it Modify the Course of Disease?
Escisión amplia en hidradenitis supurativa. ¿Modifica el curso de la enfermedad?
Visits
4620
B. Butrón-Bris, I. Lladó, E. Gallo, R. Navarro, P. Rodríguez-Jiménez1,
Corresponding author
, Y. Delgado-Jiménez1
Dermatology Department, Hospital Universitario de la Princesa, Madrid, Spain
Related content
Actas Dermosifiliogr. 2023;114:T536-T54010.1016/j.ad.2023.05.007
B. Butrón-Bris, I. Lladó, E. Gallo, R. Navarro, P. Rodríguez-Jiménez, Y. Delgado-Jiménez
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (1)
Table 1. Demographic and hidradenitis suppurativa data of our patients.
Abstract

There is a lack of studies assessing whether wide excision surgery in hidradenitis suppurativa affected areas is useful for the global control of the hidradenitis suppurativa. We aimed to find whether surgery results were a better global control on the disease activity in both, the area where the surgery is performed and distant areas. We evaluated the disease course of 17 patients with hidradenitis suppurativa who underwent wide excision of complex fistula tracts between October 2018 and January 2022 at the Hospital Universitario de la Princesa, Madrid. We found that wide excision of complex fistulas produces an overall positive effect on the inflammatory activity in hidradenitis suppurativa that may be important to achieve an adequate control of the disease.

Keywords:
Hidradenitis suppurativa
Treatment
Surgery
Resumen

No existen estudios que se centren en la utilidad del tratamiento con cirugía amplia para el control global de la hidradenitis supurativa. En el presente estudio hemos evaluado el curso de la enfermedad de 17 pacientes con hidradenitis supurativa a los que se les realizó extirpación de trayectos fistulosos mediante cirugía amplia entre octubre de 2018 y enero de 2022 en el Hospital Universitario de La Princesa. Encontramos como resultado que el tratamiento mediante cirugía amplia produce un beneficio global en la actividad inflamatoria de la enfermedad y puede ser importante para el control de la hidradenitis supurativa.

Palabras clave:
Hidradenitis supurativa
Tratamiento
Cirugía
Full Text
Introduccion

Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by relapsing painful abscesses, scars and sinus tract formation.

The multidisciplinary treatment of the disease includes medical therapies, as well as surgical options.1–3

There is a lack studies assessing the usefulness of wide local excision in the overall control of the disease. The idea that wide excision of chronic and irreversible fistulas may improve the overall activity and course of the disease, reducing flares in the intervention area and other anatomical sites has remained unexplored. We aimed to determine whether surgery results were a better global control on the disease activity and reducing flare ups in both: the area where the surgery is performed, and distant areas.

Case series and methods

We designed a retrospective study that reviewed all patients with a diagnosis of moderate to severe hidradenitis suppurativa (Hurley score ≥2) who underwent wide excision of complex fistula tracts between October 2018 and January 2022 at our center. Patients were selected as they presented one or two (n=3 patients) predominantly affected areas to perform surgery.

We collected: demographic parameters (age, gender, body weight and smoking history); HS parameters (duration of HS symptoms before surgery, number of flares previous to the surgery, localization of the lesion, previous treatments and number of flares after the surgery); and surgery satisfaction and complications (Table 1). We considered flare ups as the development of new lesions that required intensification or initiation of treatment to control the disease: both as local recurrence and in a distant anatomical site, while analyzing both locations separately.

Table 1.

Demographic and hidradenitis suppurativa data of our patients.

N  Age  Gender  Localization of the lesion  Hurley (baseline)  Classification of fistulas  Previous treatments  Reconstruction  Follow up(months) 
32  Right axilla  III  AB+ADA  Local flap  12 
43  Right axilla  III  AB  Local flap  12 
30  Right buttock  III  AB  Graf  12 
50  Right axilla  III  AB+ADA  Local flap  12 
57  Left groin  II  AB  Direct closure  12 
58  Right axilla and left groin  III  AB  Direct closure  12 
33  Left groin  II  AB  Direct closure  12 
20  Right and left axilla  III  B/C  AB+ADA  Local flap  12 
44  Left axilla  II  AB  Local flap  12 
10  53  Right and left axilla  III  C/C  AB  Local flap  12 
11  41  Genital  II  AB  Direct closure  12 
13  59  Perianal  II  AB  Direct closure  12 
14  21  Right and left axilla  II  B/C  AB  Local flap  12 
15  17  Genital  III  AB  Local flap 
16  62  Right groin  II  AB  Local flap  12 
17  60  Right groin  II  AB  Direct closure  12 

AB: antibiotic; ADA: adalimumab.

HS severity was assessed with the International Hidradenitis Suppurativa Severity Score System (IHS4) and Martorell ultrasound classification of fistulas.4,5 Data were evaluated at 6, 3 and 1 month before and after the surgical procedure. Sixteen patients completed a 12 month follow up. The surgical technique used was wide local surgical excision, which consisted in: using local or tumescent anesthesia, the removal of an entire affected area, reaching clinically disease free subcutaneous fatty tissue, followed by reconstruction and not by second intention healing (Fig. 1).

Figure 1.

Wide local surgical excision. (a) Axilla with hidradenitis suppurativa lesions (Hurley III). (b) Removal of an entire affected area, reaching clinically disease free subcutaneous fatty tissue. (c) Reconstruction with advancement flap to repair the surgical defect.

(0.25MB).

Descriptive statistics were performed using SPSS software ver. 22.0 (IBM®, Armonk, NY, USA) and expressed as means and ranges.

Results

Seventeen patients, who accounted for twenty wide excisions, were included in the study. Mean age was 44 years (21–62 years), 11 patients (64.7%) were woman. Most of the patients were obese (70.59%; 12/17) and had a positive history of smoking (82.35%; 14/17).

The average time between disease onset and surgery was 15.4 years (2–31 years). Regarding disease severity, 58.8% (10/17) of patients presented Hurley stage II and 41.2% (7/17) presented stage III. Most surgeries were performed in the axilla (11) followed by the inguinal (4), genital (3) and gluteal–perineal region (2).

A large proportion of patients (65%; 13/20) presented between 3 and 6 flares within 6 months before surgery and four patients (20%; 4/20) suffered subintrant flares before the surgical intervention (Fig. 2a).

Figure 2.

Reduction of local and distant flares after surgery. Graph shows percentage of patients presenting different number of flares (1–5) or subintrant flares (>6), including local and distant locations. (a) Six months prior to surgery. (b) Six-month follow-up.

(0.14MB).

Before surgery, all patients were treated with at least 1 cycle of oral antibiotic and three patients were under treatment with adalimumab. There were several periods of treatment with subsequent discontinuation due to lack of response or disease control: patient 3 (33 months), patient 4 (23 months) and patient 8 (25 months). Ten type B, 9 type C and one type D fistulas were surgically treated. The types of reconstruction performed were either local flap (9/20), direct closure (10/20) or skin graft (1/20). Surgery complications were 2/17 moderate pain that required analgesia, 1/17 seroma and 1/17 wound infection.

With a mean follow up of 11.65 months, local recurrence rate was 10% (2/20), at locations previously affected by the disease, and 15 from 17 patients (88.2%) remained without inflammatory activity (Fig. 2b) and did not need further antibiotic therapy.

At a six month follow up 40% (8/20) remained free of disease globally and 50% (10/20) presented mild activity (IHS43). (Fig. 3).

Figure 3.

Reduction of disease severity after surgery. Graph shows percentage of patients with different degrees of disease severity according to the International Hidradenitis Suppurativa Severity Score System (IHS4). (a) Six months prior to surgery (average). (b) At six-month of follow up. (c) Baseline IHS4 and after surgery (6 months).

(0.34MB).

Regarding satisfaction, all patients were satisfied with the esthetic results and declared that they would undergo the same surgical procedure again if necessary.

Discussion

Fistulous tracts are considered as one of the most important signs of severity in HS because of their capacity to generate irreversible structures that require surgical management.2

Previous reports in the literature on the use of wide local excision in HS, was mainly focused on local recurrence.2

At the time of writing wide excision is accepted as an adequate surgical choice, with a lower local recurrence rate (13–33%), depending on the follow up period, surgery location and closure method.6,7 In our case study, the recurrence rate in the intervened area after wide excision of complex fistulas was 10%. Walters et al. were one of the few authors who reported that when performing surgery on both local and distant flare ups also improved in anatomical areas which were different from those that underwent surgery.8

Our results show an important decrease in the inflammatory activity after surgery: flares were reduced a mean of 77.8%. Similarly, disease severity was greatly reduced after surgery: six months after surgery most of the patients did not develop new symptoms [IHS4=0] or maintained mild activity [IHS43]). As a consequence of reduction in flares, the use of antibiotics through follow up was lower than that of the six months prior to surgery. Regarding patient satisfaction, 100% of the patients were satisfied with the outcome of the surgery and claimed that they would undergo the same surgical procedure again if they presented similar lesions to those previously operated.

The present study has some limitations. Firstly, the sample size is small and the follow up is short. Secondly, although HS has an important impact on patient's life,9,10 we did not use questionnaires to assess changes in quality of life.

Conclusions

Results from our series suggest that wide excision of complex fistulas (type B, C and D) improve HS control, by reducing the number of flares at the surgical site and at distant locations. Consequently, the use of oral and topical antibiotics was also reduced. This procedure presents low recurrence and provides high patient satisfaction with the surgery and the aesthetic results. These results warrant further validation studies with larger cohorts and long term follow up.

Conflict of interests

The authors declare they have no conflict of interest.

References
[1]
C.C. Zouboulis, N. Desai, L. Emtestam, R.E. Hunger, D. Ioannides, I. Juhász, et al.
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.
J Eur Acad Dermatol Venereol, 29 (2015), pp. 619-644
[2]
C. Posch, B. Monshi, T. Quint, et al.
The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): retrospective analysis of 74 patients.
J Am Acad Dermatol, 77 (2017), pp. 123-129
[3]
D.C. Van Rappard, J.R. Mekkes.
Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions.
Br J Dermatol, 167 (2012), pp. 206-208
[4]
A. Martorell, G. Giovanardi, P. Gomez-Palencia, V. Sanz-Motilva.
Defining fistular patterns in hidradenitis suppurativa: impact on the management.
Dermatol Surg, 45 (2019), pp. 1237-1244
[5]
C.C. Zouboulis, T. Tzellos, A. Kyrgidis, G.B.E. Jemec, F.G. Bechara, E.J. Giamarellos-Bourboulis, et al.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Br J Dermatol, 177 (2017), pp. 1401-1409
[6]
A. Mehdizadeh, P.G. Hazen, F.G. Bechara, N. Zwingerman, M. Moazenzadeh, M. Bashash, et al.
Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis.
J Am Acad Dermatol, 73 (2015), pp. 70-77
[7]
Z.N. Ovadja, M. Zugaj, W. Jacobs, C.M.A.M. van der Horst, O. Lapid.
Recurrence rates following reconstruction strategies after wide excision of hidradenitis suppurativa: a systematic review and meta-analysis.
Dermatol Surg, 47 (2021), pp. 106-110
[8]
A.C. Walter, M. Meissner, R. Kaufmann, E. Valesky, A. Pinter.
Hidradenitis suppurativa after radical surgery-long-term follow-up for recurrences and associated factors.
Dermatol Surg, 44 (2018), pp. 1323-1331
[9]
L.M. Prens, J. Huizinga, I.C. Janse, B. Horváth.
Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.
J Eur Acad Dermatol Venereol, 33 (2019), pp. 1941-1946
[10]
L. Kofler, K. Schweinzer, M. Heister, M. Kohler, H. Breuninger, H.M. Häfner.
Surgical treatment of hidradenitis suppurativa: an analysis of postoperative outcome, cosmetic results and quality of life in 255 patients.
J Eur Acad Dermatol Venereol, 32 (2018), pp. 1570-1574

Both co-authors have worked equally in the supervision of this manuscript.

Copyright © 2023. AEDV
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?